Surveyed Canadian pediatric tertiary hospitals show 72.2% maintain pediatric-specific massive hemorrhage protocols (MHPs), 92.3% of those recommend initial ratio-based blood component transfusion, and 61.5% stage only red blood cells in the first transport container — highlighting dangerous protocol and kit variability. Concurrently, cybersecurity ML research identifies persistent blind spots (drive‑by downloads, post‑compromise SQLi) that favor data‑rich incumbents and attract R&D and venture capital. Implications: operators must codify deterministic MHP playbooks into EHRs, automate kit fulfillment and inventory forecasting, deploy end‑to‑end telemetry with provenance, and harden ML pipelines against adversarial poisoning. Investors should prioritize firms with proprietary labeled datasets, recurring SaaS models, and demonstrated clinical or detection efficacy; expect capital rotation from legacy signature vendors to ML/platforms and clinical workflow SaaS. Business development should pursue partnerships with EHRs, blood suppliers, and SOC/platform vendors to deliver turnkey pediatric MHP registries, kitting and audit dashboards, and OEM ML modules for niche attack classes. Recommended immediate actions: standardize pediatric MHP templates and container contents; run pilots integrating activation dashboards and kitting; fund hybrid sequence‑graph‑probabilistic ML research and deploy secure telemetry/automation stacks with human‑in‑the‑loop escalation. Measure outcomes via detection time, time‑to‑transfusion, blood waste reduction, and compliance rates to validate ROI and guide scale‑up nationwide rollout.